Author: admin

Small Cell Lung Cancer Market Expected to rise, 2034 | Ipsen Biopharmaceuticals, BMS, Xcovery Holding Company, EpicentRx, Amgen, expected to rise

“Small Cell Lung Cancer market growth 2034”
The Small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Small Cell Lung Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, share, Small Cell Lung Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Small Cell Lung Cancer market size growth forward.

Some of the key highlights from the Small Cell Lung Cancer Market Insights Report:

  • As per DelveInsight analysis, the Small Cell Lung Cancer market is anticipated to witness growth at a considerable CAGR

  • Several key pharmaceutical companies, including Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, Amgen, and others, are developing novel products to improve the Small Cell Lung Cancer treatment outlook.

  • In December 2024, Xcovery Holdings, Inc. announced that the U.S. Food and Drug Administration has approved ensartinib (Ensacove) for treating patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval represents a significant step forward in offering a new first-line treatment option for patients with ALK-positive NSCLC.

  • In September 2024, AbbVie filed a biologics license application (BLA) with the FDA, requesting accelerated approval for telisotuzumab vedotin (Teliso-V) to treat patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) that shows c-Met protein overexpression.

  • According to DelveInsight, the Small Cell Lung Cancer (SCLC) market is expected to experience significant growth between 2024 and 2034, driven by the introduction of new therapies and a rise in the number of cases. Lung cancer affects over 200,000 people annually in the United States and an estimated 2.3 million globally. Small Cell Lung Cancer accounts for 10% to 15% of lung cancer cases. The 5-year relative survival rate for individuals with SCLC in the U.S. is 8% for women and 6% for men.

  • Treatments for SCLC include IMFINZI (durvalumab) for extensive-stage SCLC and ZEPZELCA (lurbinectedin) for metastatic cases. Approximately 25% of individuals with limited-stage SCLC can be cured with timely chemotherapy and radiation therapy. The long-standing treatment approach involves platinum etoposide, with topotecan serving as a second-line option for those who respond well to platinum-based therapies. Although topotecan has a response rate of around 20%, its survival benefit is limited compared to the best supportive care.

  • The number and effectiveness of SCLC treatments remain far behind those for non-Small Cell Lung Cancer, which has seen significant advancements in targetable therapies and better responses to immunotherapy. Recently, immunotherapy has shown promise for SCLC, but challenges regarding toxicity and efficacy remain, and additional treatment options are needed to address the disease’s various subtypes. Key companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), and Amgen (AMG 757) are advancing their lead candidates through various stages of clinical development.

  • In 2023, it is estimated that there will be approximately 238,340 new cases of lung cancer in the United States, with 117,550 cases in men and 120,790 cases in women. The statistics typically include both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). SCLC accounts for about 10% to 15% of all lung cancers, while NSCLC makes up approximately 80% to 85%.

  • In the U.S., Small Cell Lung Cancer is slightly more common in women (14%) than in men (13%). The risk of developing lung cancer increases with age, and both men and women are most likely to be diagnosed with Small Cell Lung Cancer between the ages of 75 and 79.

  • In the UK, around 15% to 20% of all lung cancer diagnoses are Small Cell Lung Cancer, which is primarily caused by smoking. This type of cancer tends to spread early in its progression.

Strategise your business goals by understanding market dynamics @ Small Cell Lung Cancer Market Landscape

Small Cell Lung Cancer Overview

Small Cell Lung Cancer (SCLC) is a highly aggressive form of lung cancer characterized by the rapid and uncontrolled growth of cells within the lungs, often leading to tumor development and metastasis to other parts of the body. Smoking is the primary risk factor, with almost all cases occurring in individuals who currently smoke or have a history of smoking. Early stages of the disease typically present no noticeable symptoms, and when symptoms do appear, they can vary widely among patients.

To diagnose lung cancer, doctors usually recommend imaging tests like CT, PET, or MRI scans to identify any lung abnormalities. A mucus sample may also be analyzed for cancer cells. If cancer is suspected, a biopsy — involving either a needle insertion or a small surgical procedure — is performed to collect lung tissue for examination. Bronchoscopy is another common technique used to view the lungs directly and obtain tissue samples.

Do you know the treatment paradigms for different countries? Download our Small Cell Lung Cancer Market Sample Report

Small Cell Lung Cancer Epidemiology Segmentation

DelveInsight’s Small Cell Lung Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Small Cell Lung Cancer historical patient pools and forecasted Small Cell Lung Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Small Cell Lung Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Small Cell Lung Cancer Prevalence

  • Age-Specific Small Cell Lung Cancer Prevalence

  • Gender-Specific Small Cell Lung Cancer Prevalence

  • Diagnosed and Treatable Cases of Small Cell Lung Cancer

Visit for more @ Small Cell Lung Cancer Epidemiological Insights

Small Cell Lung Cancer Treatment Market

Over the past 30 years, progress in improving survival rates for Small Cell Lung Cancer (SCLC) patients has been minimal, largely due to the cancer’s aggressive growth, early metastasis, and resistance to chemotherapy. Treatment decisions are based on the cancer stage, patient health, and personal preferences, and may involve surgery, chemotherapy, radiation, or immunotherapy. Standard chemotherapy typically includes Etoposide or Irinotecan with a platinum-based drug like Cisplatin or Carboplatin. Limited-stage SCLC is treated with combined chemotherapy and radiation, while extensive-stage disease often involves chemotherapy, sometimes paired with immunotherapy.

Recent advancements have introduced immune checkpoint inhibitors like nivolumab, pembrolizumab, atezolizumab, and durvalumab for first-line therapy. Lurbinectedin is now approved for second-line treatment, and trilaciclib helps prevent chemotherapy-induced myelosuppression. However, in 2021, approvals for nivolumab and pembrolizumab in later-stage treatment were withdrawn, though they remain in use alongside other therapies.

Research is ongoing to develop new treatments, with hopes that biomarker-driven approaches will significantly improve outcomes, much like in non-Small Cell Lung Cancer (NSCLC). Companies like Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen are actively advancing new therapies through clinical trials.

Small Cell Lung Cancer Marketed Drugs

  • ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals

  • IMFINZI (durvalumab): AstraZeneca

Small Cell Lung Cancer Emerging Drugs

  • RRx-001: EpicentRx

Small Cell Lung Cancer Key Companies

  • Bristol-Myers Squibb

  • Merck

  • AstraZeneca

  • PharmaMar

  • EpicentRx

  • And others

For more information, visit Small Cell Lung Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Small Cell Lung Cancer Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Small Cell Lung Cancer, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Small Cell Lung Cancer epidemiology in the 7MM

  • Small Cell Lung Cancer marketed and emerging therapies

  • Small Cell Lung Cancer companies

  • Small Cell Lung Cancer market drivers and barriers

Table of Contents:

1 Small Cell Lung Cancer Market Key Comprehensive Insights

2 Small Cell Lung Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Small Cell Lung Cancer

4 Small Cell Lung Cancer Market Analysis Overview at a Glance

5 Executive Summary of Small Cell Lung Cancer

6 Small Cell Lung Cancer Epidemiology and Market Methodology

7 Small Cell Lung Cancer Epidemiology and Patient Population

8 Small Cell Lung Cancer Patient Journey

9 Small Cell Lung Cancer Treatment Algorithm, Small Cell Lung Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Small Cell Lung Cancer Clinical Trials

11 Small Cell Lung Cancer Marketed Therapies

12 Small Cell Lung Cancer Emerging Therapies

13 Small Cell Lung Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Small Cell Lung Cancer

16 Small Cell Lung Cancer Market Key Opinion Leaders Reviews

18 Small Cell Lung Cancer Market Drivers

19 Small Cell Lung Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Small Cell Lung Cancer Epidemiology 2034

DelveInsight’s “Small Cell Lung Cancer – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Small Cell Lung Cancer Pipeline 2024

“Small Cell Lung Cancer Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Small Cell Lung Cancer market. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Cell Lung Cancer Market Expected to rise, 2034 | Ipsen Biopharmaceuticals, BMS, Xcovery Holding Company, EpicentRx, Amgen, expected to rise

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market

“Atypical hemolytic uremic syndrome market growth 2034”
The atypical hemolytic uremic syndrome market growth is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The atypical hemolytic uremic syndrome market growth is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Atypical Hemolytic Uremic Syndrome market report also offers comprehensive insights into the Atypical Hemolytic Uremic Syndrome market size, share, Atypical Hemolytic Uremic Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Atypical Hemolytic Uremic Syndrome market size growth forward.

Some of the key highlights from the Atypical Hemolytic Uremic Syndrome Market Insights Report:

  • As per DelveInsight analysis, the Atypical Hemolytic Uremic Syndrome market is anticipated to witness growth at a considerable CAGR

  • Several key pharmaceutical companies, including Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others, are developing novel products to improve the Atypical Hemolytic Uremic Syndrome treatment outlook.

  • In April 2024, Hoffmann-La Roche revealed the results of a Phase III, multicenter, single-arm study assessing the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).

  • In February 2024, Alexion Pharmaceuticals, Inc. announced the results of a prospective, single-arm, multicenter study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in complement inhibitor treatment-naïve pediatric and adult patients with aHUS in China.

  • In 2023, the United States had the largest market share for Atypical Hemolytic Uremic Syndrome (aHUS) among the 7MM, and this market is expected to grow with a compound annual growth rate (CAGR) of approximately 4% by 2034.

  • There are two types of HUS: Typical HUS, caused by pathogens like E. coli, and atypical HUS, which is often linked to genetic mutations, but can also be triggered by illnesses or other unknown causes. Most aHUS cases are genetic, although some can be acquired through autoantibodies or idiopathic causes. The condition can become chronic, leading to complications such as hypertension and kidney failure.

  • The disease is related to gene mutations and triggering events, like pregnancy, infections, cancers, and certain medications. The clinical manifestations of aHUS can involve various organ systems, including renal, hematologic, respiratory, ocular, skin, CNS, cardiovascular, and GI systems.

  • Diagnosis includes a complete blood count (CBC) to measure red blood cell and platelet counts, and an estimated glomerular filtration rate (eGFR) to assess kidney function.

  • In 2023, there were nearly 4,800 diagnosed cases of aHUS in the 7MM, with the majority of cases being in adults and adolescents (around 4,000 cases) compared to pediatric cases (approximately 700 cases).

  • Currently, only eculizumab and ravulizumab are approved for treatment, both developed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021. Iptacopan (LNP023), an oral drug by Novartis, is in Phase III trials and could become a preferred treatment due to its convenient oral administration. It is expected to generate over USD 500 million by 2034.

Strategise your business goals by understanding market dynamics @ Atypical Hemolytic Uremic Syndrome Market Landscape

Atypical Hemolytic Uremic Syndrome Overview

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare disorder marked by the destruction of red blood cells (causing hemolytic anemia), a reduced platelet count (thrombocytopenia), and acute kidney failure (uremia), which compromises the kidneys’ ability to eliminate waste. In aHUS, red blood cells break apart as they move through clots in small blood vessels, and if the body can’t produce new cells fast enough, anemia develops. This process can severely damage the kidneys, with about half of affected individuals progressing to end-stage renal disease (ESRD).

Diagnosing aHUS is often difficult, particularly in cases without a clear family history. It is primarily based on the combination of hemolytic anemia, low platelet levels, and signs of kidney impairment.

Treatment strategies focus on managing kidney injury and associated complications. Severe anemia may require transfusions of packed red blood cells, while platelet transfusions are reserved for extreme cases. Careful management of fluids and electrolytes is critical, nephrotoxic drugs should be avoided, and blood pressure must be controlled. In instances of kidney failure, renal replacement therapy may be needed. Targeted therapies such as plasma exchange and complement inhibitors, including eculizumab and ravulizumab, address the root cause of the disease.

Do you know the treatment paradigms for different countries? Download our Atypical Hemolytic Uremic Syndrome Market Sample Report

Atypical Hemolytic Uremic Syndrome Epidemiology Insights

  • DelveInsight’s epidemiology model estimates that there were approximately 5K diagnosed cases of aHUS across the 7MM in 2023, with this number expected to rise throughout the forecast period.

  • The United States had the highest number of aHUS cases, with nearly 3,500 cases reported in 2023, and this figure is projected to increase by 2034.

  • Among the 7MM, adolescents and adults made up about 80% of the diagnosed cases in 2023.

Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation

DelveInsight’s Atypical Hemolytic Uremic Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Atypical Hemolytic Uremic Syndrome historical patient pools and forecasted Atypical Hemolytic Uremic Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Atypical Hemolytic Uremic Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Atypical Hemolytic Uremic Syndrome Prevalence

  • Age-Specific Atypical Hemolytic Uremic Syndrome Prevalence

  • Gender-Specific Atypical Hemolytic Uremic Syndrome Prevalence

  • Diagnosed and Treatable Cases of Atypical Hemolytic Uremic Syndrome

Visit for more @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights

Atypical Hemolytic Uremic Syndrome Market Insights:

  • Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Atypical Hemolytic Uremic Syndrome (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.

  • According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was USD 1.3 billion in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.

  • In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.

  • Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Atypical Hemolytic Uremic Syndrome Market Outlook

The introduction of complement C5 inhibition has significantly enhanced patient outcomes and quality of life (QoL) in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). The available complement C5 inhibitors in the 7MM are SOLIRIS (eculizumab) and ULTOMIRIS (ravulizumab), both products of Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021.

Switching patients from eculizumab to ravulizumab has proven to be an effective treatment strategy. This transition reduces the frequency of dosing, resulting in lower treatment-related costs and improved patient QoL.

Despite their proven safety and effectiveness, the high cost of eculizumab and ravulizumab limits their accessibility in the treatment landscape. As a result, there is a significant need for more effective pharmacological options, especially for managing the more severe and disabling stages of aHUS.

While several promising therapies are under investigation for aHUS, it is too early to confirm which will enter the market during the forecast period (2024–2034). However, it is clear that the future of this market holds promise. These new treatments are expected to bring substantial improvements to the aHUS treatment landscape in the coming years, driven by increasing global healthcare spending.

Atypical Hemolytic Uremic Syndrome Marketed Drugs

  • ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals

  • SOLIRIS (eculizumab): Alexion Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Emerging Drugs

  • Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical

  • FABHALTA (iptacopan): Novartis Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Key Companies

  • Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others

Scope of the Atypical Hemolytic Uremic Syndrome Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Atypical Hemolytic Uremic Syndrome, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM

  • Atypical Hemolytic Uremic Syndrome marketed and emerging therapies

  • Atypical Hemolytic Uremic Syndrome companies

  • Atypical Hemolytic Uremic Syndrome market drivers and barriers

Table of Contents:

1 Atypical Hemolytic Uremic Syndrome Market Key Comprehensive Insights

2 Atypical Hemolytic Uremic Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome

4 Atypical Hemolytic Uremic Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Atypical Hemolytic Uremic Syndrome

6 Atypical Hemolytic Uremic Syndrome Epidemiology and Market Methodology

7 Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population

8 Atypical Hemolytic Uremic Syndrome Patient Journey

9 Atypical Hemolytic Uremic Syndrome Treatment Algorithm, Atypical Hemolytic Uremic Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Atypical Hemolytic Uremic Syndrome Clinical Trials

11 Atypical Hemolytic Uremic Syndrome Marketed Therapies

12 Atypical Hemolytic Uremic Syndrome Emerging Therapies

13 Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome

16 Atypical Hemolytic Uremic Syndrome Market Key Opinion Leaders Reviews

18 Atypical Hemolytic Uremic Syndrome Market Drivers

19 Atypical Hemolytic Uremic Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Atypical Hemolytic Uremic Syndrome Epidemiology 2034

DelveInsight’s “Atypical Hemolytic Uremic Syndrome – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Atypical Hemolytic Uremic Syndrome Pipeline 2024

“Atypical Hemolytic Uremic Syndrome Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Atypical Hemolytic Uremic Syndrome market. A detailed picture of the Atypical Hemolytic Uremic Syndrome pipeline landscape is provided, which includes the disease overview and Atypical Hemolytic Uremic Syndrome treatment guidelines.

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected to Drive Market

The atypical hemolytic uremic syndrome market growth is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Atypical Hemolytic Uremic Syndrome market report also offers comprehensive insights into the Atypical Hemolytic Uremic Syndrome market size, share, Atypical Hemolytic Uremic Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Atypical Hemolytic Uremic Syndrome market size growth forward.

Some of the key highlights from the Atypical Hemolytic Uremic Syndrome Market Insights Report:

  • As per DelveInsight analysis, the Atypical Hemolytic Uremic Syndrome market is anticipated to witness growth at a considerable CAGR

  • Several key pharmaceutical companies, including Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others, are developing novel products to improve the Atypical Hemolytic Uremic Syndrome treatment outlook.

  • In April 2024, Hoffmann-La Roche revealed the results of a Phase III, multicenter, single-arm study assessing the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).

  • In February 2024, Alexion Pharmaceuticals, Inc. announced the results of a prospective, single-arm, multicenter study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in complement inhibitor treatment-naïve pediatric and adult patients with aHUS in China.

  • In 2023, the United States had the largest market share for Atypical Hemolytic Uremic Syndrome (aHUS) among the 7MM, and this market is expected to grow with a compound annual growth rate (CAGR) of approximately 4% by 2034.

  • There are two types of HUS: Typical HUS, caused by pathogens like E. coli, and atypical HUS, which is often linked to genetic mutations, but can also be triggered by illnesses or other unknown causes. Most aHUS cases are genetic, although some can be acquired through autoantibodies or idiopathic causes. The condition can become chronic, leading to complications such as hypertension and kidney failure.

  • The disease is related to gene mutations and triggering events, like pregnancy, infections, cancers, and certain medications. The clinical manifestations of aHUS can involve various organ systems, including renal, hematologic, respiratory, ocular, skin, CNS, cardiovascular, and GI systems.

  • Diagnosis includes a complete blood count (CBC) to measure red blood cell and platelet counts, and an estimated glomerular filtration rate (eGFR) to assess kidney function.

  • In 2023, there were nearly 4,800 diagnosed cases of aHUS in the 7MM, with the majority of cases being in adults and adolescents (around 4,000 cases) compared to pediatric cases (approximately 700 cases).

  • Currently, only eculizumab and ravulizumab are approved for treatment, both developed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021. Iptacopan (LNP023), an oral drug by Novartis, is in Phase III trials and could become a preferred treatment due to its convenient oral administration. It is expected to generate over USD 500 million by 2034.

Strategise your business goals by understanding market dynamics @ Atypical Hemolytic Uremic Syndrome Market Landscape

Atypical Hemolytic Uremic Syndrome Overview

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare disorder marked by the destruction of red blood cells (causing hemolytic anemia), a reduced platelet count (thrombocytopenia), and acute kidney failure (uremia), which compromises the kidneys’ ability to eliminate waste. In aHUS, red blood cells break apart as they move through clots in small blood vessels, and if the body can’t produce new cells fast enough, anemia develops. This process can severely damage the kidneys, with about half of affected individuals progressing to end-stage renal disease (ESRD).

Diagnosing aHUS is often difficult, particularly in cases without a clear family history. It is primarily based on the combination of hemolytic anemia, low platelet levels, and signs of kidney impairment.

Treatment strategies focus on managing kidney injury and associated complications. Severe anemia may require transfusions of packed red blood cells, while platelet transfusions are reserved for extreme cases. Careful management of fluids and electrolytes is critical, nephrotoxic drugs should be avoided, and blood pressure must be controlled. In instances of kidney failure, renal replacement therapy may be needed. Targeted therapies such as plasma exchange and complement inhibitors, including eculizumab and ravulizumab, address the root cause of the disease.

Do you know the treatment paradigms for different countries? Download our Atypical Hemolytic Uremic Syndrome Market Sample Report

Atypical Hemolytic Uremic Syndrome Epidemiology Insights

  • DelveInsight’s epidemiology model estimates that there were approximately 5K diagnosed cases of aHUS across the 7MM in 2023, with this number expected to rise throughout the forecast period.

  • The United States had the highest number of aHUS cases, with nearly 3,500 cases reported in 2023, and this figure is projected to increase by 2034.

  • Among the 7MM, adolescents and adults made up about 80% of the diagnosed cases in 2023.

Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation

DelveInsight’s Atypical Hemolytic Uremic Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Atypical Hemolytic Uremic Syndrome historical patient pools and forecasted Atypical Hemolytic Uremic Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Atypical Hemolytic Uremic Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Atypical Hemolytic Uremic Syndrome Prevalence

  • Age-Specific Atypical Hemolytic Uremic Syndrome Prevalence

  • Gender-Specific Atypical Hemolytic Uremic Syndrome Prevalence

  • Diagnosed and Treatable Cases of Atypical Hemolytic Uremic Syndrome

Visit for more @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights

Atypical Hemolytic Uremic Syndrome Market Insights:

  • Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Atypical Hemolytic Uremic Syndrome (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.

  • According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was USD 1.3 billion in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.

  • In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.

  • Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Atypical Hemolytic Uremic Syndrome Market Outlook

The introduction of complement C5 inhibition has significantly enhanced patient outcomes and quality of life (QoL) in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). The available complement C5 inhibitors in the 7MM are SOLIRIS (eculizumab) and ULTOMIRIS (ravulizumab), both products of Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021.

Switching patients from eculizumab to ravulizumab has proven to be an effective treatment strategy. This transition reduces the frequency of dosing, resulting in lower treatment-related costs and improved patient QoL.

Despite their proven safety and effectiveness, the high cost of eculizumab and ravulizumab limits their accessibility in the treatment landscape. As a result, there is a significant need for more effective pharmacological options, especially for managing the more severe and disabling stages of aHUS.

While several promising therapies are under investigation for aHUS, it is too early to confirm which will enter the market during the forecast period (2024–2034). However, it is clear that the future of this market holds promise. These new treatments are expected to bring substantial improvements to the aHUS treatment landscape in the coming years, driven by increasing global healthcare spending.

Atypical Hemolytic Uremic Syndrome Marketed Drugs

  • ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals

  • SOLIRIS (eculizumab): Alexion Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Emerging Drugs

  • Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical

  • FABHALTA (iptacopan): Novartis Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Key Companies

  • Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others

For more information, visit Atypical Hemolytic Uremic Syndrome Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Atypical Hemolytic Uremic Syndrome Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Atypical Hemolytic Uremic Syndrome, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM

  • Atypical Hemolytic Uremic Syndrome marketed and emerging therapies

  • Atypical Hemolytic Uremic Syndrome companies

  • Atypical Hemolytic Uremic Syndrome market drivers and barriers

Table of Contents:

1Atypical Hemolytic Uremic Syndrome Market Key Comprehensive Insights

2Atypical Hemolytic Uremic Syndrome Market Report Introduction

3Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome

4Atypical Hemolytic Uremic Syndrome Market Analysis Overview at a Glance

5Executive Summary of Atypical Hemolytic Uremic Syndrome

6Atypical Hemolytic Uremic Syndrome Epidemiology and Market Methodology

7Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population

8Atypical Hemolytic Uremic Syndrome Patient Journey

9Atypical Hemolytic Uremic Syndrome Treatment Algorithm, Atypical Hemolytic Uremic Syndrome Current Treatment, and Medical Practices

10Key Endpoints in Atypical Hemolytic Uremic Syndrome Clinical Trials

11Atypical Hemolytic Uremic Syndrome Marketed Therapies

12Atypical Hemolytic Uremic Syndrome Emerging Therapies

13Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

14Attribute analysis

15Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome

16Atypical Hemolytic Uremic Syndrome Market Key Opinion Leaders Reviews

18Atypical Hemolytic Uremic Syndrome Market Drivers

19Atypical Hemolytic Uremic Syndrome Market Barriers

20SWOT Analysis

21Disclaimer

22DelveInsight Capabilities

23About DelveInsight

Related Reports:

Atypical Hemolytic Uremic Syndrome Epidemiology 2034

DelveInsight’s “Atypical Hemolytic Uremic Syndrome – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Atypical Hemolytic Uremic Syndrome Pipeline 2024

“Atypical Hemolytic Uremic Syndrome Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Atypical Hemolytic Uremic Syndrome market. A detailed picture of the Atypical Hemolytic Uremic Syndrome pipeline landscape is provided, which includes the disease overview and Atypical Hemolytic Uremic Syndrome treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market

Delightful New Children’s Book Where is Wyatt by Ashley Kidd Sparks Laughter & Curiosity

An Engaging and Heartwarming Illustrated Tale That Captures the Playful Adventures of a Curious Toddler!

Parents and children alike are in for a delightful literary treat with Where is Wyatt, a charming and whimsical picture book by Ashley Kidd.

This gorgeously illustrated story recounts the playful antics of Wyatt, a high-spirited and ever-curious 3-year-old toddler who goes on mischief-laden hide-and-seek adventures in his home. With its interactive storyline, Where is Wyatt will soon become a household favorite at bedtime stories.

A Story That Celebrates Childhood Curiosity

What makes Where is Wyatt so special? It’s a playful celebration of childhood curiosity and imagination! With each turn of the beautifully illustrated pages of “Where’s Wyatt?” kids will get excited with anticipation as they frantically look for the little explorer hiding in the most unexpected places.

• Unpredictable Adventures: Floor vents, kitchen cabinets, even the dryer, Wyatt’s curious mind comes up with the silliest hiding spots.

• Laugh-Out-Loud Moments: This book offers enough belly laughs to entertain parent and child alike, reading an entirely new experience.

• Encourages Exploration: Although encouraging curiosity in children, this book also tends to lay down gentle rules about safe playing.

A Fun and Interactive Reading Experience

More than just a story, Where is Wyatt turns into a playful, interactive game of hide-and-seek.

• Call-and-Response Format: Energizes kids for their guesses about Wyatt’s next potential hideout.

• Strengthens Listening & Observation Skills: Invites an encouraging twist to cognitive learning in early childhood through attractive, engaging storyline.

• Perfect for Storytime: This book must be read out loud by parents, teachers, and caregivers, making it- an instant favorite for the kids.

Balancing Curiosity with Gentle Lessons on Safety

While Where is Wyatt is filled with humor and excitement, it also subtly teaches children the importance of safe exploration. The book follows Wyatt’s adventures in an age-appropriate manner, relating fun and the gentle guiding spirit of his parents.

Through an entertaining story and expressive illustrations, young readers learn about limits while also celebrating the allure of discovery. Parents can discuss safe play with their little ones as the book elicits giggles and joy from Wyatt’s crazy antics.

A Book That Brings Families Together

At its heart, Where is Wyatt is a tribute to the bond between parents and their adventurous children. Wyatt’s parents are playfully patient and amused heroes, ensuring that every small moment of playtime should be filled with laughter and love.

• Heartwarming Message: Even amid chaos, love between parents and children is unyielding.

• Relatable to Every Family: Parents will remember their own experiences, which is a recognition that makes this book a dearly held sentimental favorite.

• A Joyful Reminder: Childhood is precious at any time, with no moment too naughty to be disregarded.

A Must-Have for Every Family’s Bookshelf

Looking for a book that will spark laughter, encourage interactive reading, and capture the joy of childhood? Where is Wyatt is a must-read!

• Perfect for Ages 2-6 — Engaging storytelling for toddlers and preschoolers.

• Ideal Gift Choice — An entertaining and unforgettable gift for birthdays, baby showers, or any holiday.

• Timeless Family Favorite — A wonderful story that will grow with the child, bringing the joy of smiling faces for years to come.

Where is Wyatt by Ashley Kidd is now available for purchase. Amazon Link: https://a.co/d/fNBOomr

Get your copy today and embark on an unforgettable adventure of hide-and-seek fun!

About the Author

Ashley Kidd is a storyteller and storyteller who turns every mundane moment into heartwarming and fun stories. She draws a great deal of inspiration from her young observed lively curiosity, and her writing catches the essence of the exuberant, mischievous and indefatigable personality of childhood itself, making her books a delight for parents and little readers alike.

Media Contact
Company Name: The Empire Publishers
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.theempirepublishers.com

Fuchs Endothelial Corneal Dystrophy Market Poised for Robust Growth by 2034 | DelveInsight

“Fuchs Endothelial Corneal Dystrophy Market Report”
The fuchs endothelial corneal dystrophy market is expected to experience significant growth in the coming years, propelled by the development of innovative non-surgical therapies, an increasing disease awareness, improved diagnostic capabilities, and substantial investments in research by key Fuchs Dystrophy companies, such as Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, and Presbia, among others.

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Market Insight, Epidemiology and Market Forecast – 2034” report delivers comprehensive insights into FECD, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapeutics across the 7MM (United States, EU4, United Kingdom, and Japan). The report reveals that the FECD market size in the 7MM was approximately USD 860 million in 2023, with projections indicating substantial growth through 2034. The United States currently holds the largest market share, at approximately USD 400 million, followed by Japan. Among the EU4 countries and the UK, Germany leads with USD 90 million, followed by Italy and Spain, which have the smallest share.

Download the Fuchs endothelial corneal dystrophy market report to understand which factors are driving the FECD therapeutic market @ Fuchs Endothelial Corneal Dystrophy Market Trends.

FECD is characterized by corneal edema, guttae formation, reduced visual acuity, and can ultimately lead to corneal blindness if left untreated. The condition demonstrates higher prevalence among women and is associated with genetic factors, particularly mutations in genes including COL8A2, SLC4A11, TCF4, and ZEB12. Current diagnostic approaches include clinical examination, in vivo imaging techniques such as slit lamp examination, specular microscopy, corneal thickness measurement, and confocal microscopy, though there remains significant unmet need for improved early-stage detection methods.

According to DelveInsight’s analysis, approximately 19 million diagnosed prevalent cases of FECD were reported across the 7MM in 2023, with the United States accounting for the highest proportion at 35% of total cases among the 7MM. Conversely, Spain represented the lowest prevalence at around 7% of total cases. The condition demonstrates notable age-specific patterns, with the 50-59 age bracket showing the highest prevalence in EU4 and the United Kingdom. In Japan, grade-specific analysis revealed nearly 1.5 million cases of grade 1-3 FECD and approximately 2 million cases of grade 4-6. This trend is expected to continue during the forecasted period.

The current treatment landscape for FECD primarily revolves around symptomatic management using hyperosmotic sodium chloride solutions, steroids, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps to alleviate painful symptoms. For ruptured corneal bullae, cycloplegic agents, antibiotic ointments, patching, and bandage contact lenses may be prescribed. However, these treatments offer only temporary relief and do not address the underlying endothelial dysfunction, highlighting a critical unmet need for curative therapies.

The FECD pipeline shows promising development activity, with several noteworthy candidates. Ripasudil (K-321), developed by Kowa Pharmaceuticals, is a rho-kinase inhibitor currently in Phase III clinical trials that represents the most advanced non-surgical alternative for FECD2. Additionally, Trefoil Therapeutics’ TTHX 1114, an engineered FGF-1 delivered via intracameral injection, demonstrates significant potential for corneal endothelial regeneration. Emerging therapies like these address the substantial unmet need for alternatives to corneal transplantation, which remains the definitive but invasive treatment option for advanced cases.

Unlock which fuchs endothelial corneal dystrophy emerging drugs is expected to capture the largest market share in 7MM by 2034. Visit the Fuchs Endothelial Corneal Dystrophy Market Insights.

Design Therapeutics’ DT-168, a GeneTAC small molecule delivered via eye drops, has emerged as a groundbreaking candidate for Fuchs endothelial corneal dystrophy. By March 2025, the company announced the completion of dosing in a Phase I Multiple Ascending Dose (MAD) clinical trial of DT-168 in healthy volunteers, with data still on track for the first half of 2025.

The market is expected to witness substantial growth driven by several factors, including increased disease awareness, improved diagnostic techniques, the introduction of novel therapeutic approaches, and a growing patient population amenable to non-surgical interventions. Despite these positive trends, challenges remain, including the high cost of innovative therapies, which can potentially limit access, and the need for improved early detection methods to enable intervention before significant endothelial damage occurs.

Discover evolving trends in the Fuchs endothelial corneal dystrophy treatment landscape @ Fuchs Endothelial Corneal Dystrophy Recent Developments.

Looking ahead, the FECD market landscape appears poised for transformation with the potential approval of Ripasudil and other pipeline candidates. The integration of advanced diagnostic technologies, including AI-driven tools and specialized imaging techniques, will likely enhance early detection capabilities, enabling more timely interventions. Additionally, ongoing research into the genetic and molecular underpinnings of FECD may unveil new therapeutic targets, further expanding treatment options for this progressive corneal condition that significantly impacts patients’ quality of life.

Table of Contents

1. Key Insights

2. Report Introduction

3. FECD Market Overview at a Glance

4. Methodology of FECD Epidemiology and Market

5. Executive Summary of FECD

6. Key Events

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Emerging Drugs

11. FECD: Market Analysis

12. KOL Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Related Reports

Fuchs Endothelial Corneal Dystrophy Pipeline Insight

Fuchs endothelial corneal dystrophy Pipeline Insight Report provides comprehensive insights about the FECD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Fuchs endothelial corneal dystrophy companies, including Trefoil Therapeutics, Kowa Pharmaceutical, and Santen Pharmaceutical, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fuchs Endothelial Corneal Dystrophy Market Poised for Robust Growth by 2034 | DelveInsight

Dermatoscope Market Projected to Reach USD 2 Billion by 2030, Growing at a CAGR of 13.30% | DelveInsight

“Dermatoscopes Market Report”
The global dermatoscope market is experiencing robust growth, driven by several factors. Key dermatoscope manufacturers include Canfield Scientific, Inc., FotoFinder Systems GmbH, DermLite, Firefly Global, Caliber Imaging and Diagnosis, Optilia Medical, Baxter, Bio-Therapeutic, HEINE Optotechnik GmbH & Co. KG, ILLUCO, Courage+Khazaka electronic GmbH, Rudolf Riester GmbH, AnMo Electronics Corporation, NIDEK CO., LTD., and KIRCHNER & WILHELM GmbH + Co. KG, among others.

DelveInsight’s “Dermatoscope Market Insight, Competitive Landscape and Market Forecast – 2030” report provides comprehensive insights into the dermatoscope market dynamics, including historical trends, current landscape, and future projections across various segments in the global market. The report analyzes the market by product type (contact dermatoscope, non-contact dermatoscope, and hybrid dermatoscope), technology (LED, xenon, halogen, and ultraviolet), portability (hand-held, trolley mounted, and headband), end-user (hospitals, dermatology clinics, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

According to DelveInsight’s latest analysis, the dermatoscope market, valued at approximately USD 900 million in 2023, is expected to expand at a significant CAGR of 13.30% during the forecast period from 2024 to 2030, reaching USD ~2 billion by 2030. This growth trajectory reflects the rising awareness about skin cancer detection, increasing adoption of advanced diagnostic techniques, and a growing emphasis on early detection of skin disorders such as melanoma, which is critical for improving patient outcomes and reducing mortality rates.

Download the Dermatoscope Market Forecast Report to understand which factors are driving the Dermatoscope therapeutic market @ Dermatoscope Market Trends.

The dermatoscope market expansion is primarily fueled by the alarming rise in skin cancer cases globally. According to the World Health Organization, more than 325K new cases of melanoma were diagnosed worldwide in 2020. In the United States alone, the Centers for Disease Control and Prevention reported approximately 89K new cases of melanomas of the skin in 2019, underscoring the critical need for advanced diagnostic tools for early detection and improved patient outcomes.

Technological advancements represent another significant growth driver in the dermatoscope market. Leading companies are investing heavily in research and development to introduce innovative products featuring enhanced imaging capabilities, artificial intelligence integration, and improved portability. For instance, in November 2020, Barco launched a revolutionary skin imaging platform called Demetra, which combines AI technology with an innovative design, enabling dermatologists to make faster and more accurate diagnoses. Similarly, in January 2021, Casio Computer Co., Ltd. introduced the DZ-D100 DERMOCAMERA, which allows for both close-up shots with the lens directly touching the skin and ordinary shots using a single camera.

North America currently dominates the global dermatoscope market, accounting for the largest share. This regional leadership is attributed to the high prevalence of skin-related diseases, robust healthcare infrastructure, presence of key market players, and growing government initiatives to raise awareness about skin cancer detection and treatment. Additionally, the economic burden of skin cancer treatment in the US, estimated at around $5 billion annually for basal cell and squamous cell carcinomas, has intensified the focus on early diagnosis and prevention strategies, further driving the demand for advanced dermatoscopes.

The competitive landscape of the dermatoscope market features several prominent players, including Canfield Scientific, Inc., FotoFinder Systems GmbH, DermLite, Firefly Global, Caliber Imaging and Diagnosis, Optilia Medical, Baxter, Bio-Therapeutic, HEINE Optotechnik GmbH & Co. KG, ILLUCO, Courage+Khazaka electronic GmbH, Rudolf Riester GmbH, AnMo Electronics Corporation, NIDEK CO., LTD., and KIRCHNER & WILHELM GmbH + Co. KG, among others. These companies are actively engaged in product innovations, strategic partnerships, and mergers and acquisitions to strengthen their market position.

Download the Dermatoscope Competitive Landscape Report for in-depth dermatoscope competitive insights.

The global dermatoscope market is experiencing a dynamic phase of competition as leading companies race to bring advanced diagnostic technologies to dermatology clinics and hospitals worldwide. One of the most significant developments as of 2025 is the integration of artificial intelligence with dermatoscopes. Companies are incorporating AI-powered diagnostics to enhance precision and efficiency in skin disease detection.

Another notable development is dermatoscopes with advanced smartphone connectivity capabilities, allowing for remote consultations and expanding access to dermatological care. This telemedicine functionality has gained significant traction in the market, enabling specialists to provide diagnoses without in-person visits.

Notable recent developments in the competitive landscape include HEINE Optotechnik’s introduction of two new dermatoscopes in October 2019 – DELTA 30 and DELTAone – featuring fully optimized achromatic optical systems for crystal-clear imaging. Within specific market segments, LED dermatoscopes are expected to capture a significant revenue share in 2023, owing to advantages such as brighter illumination, enhanced ergonomics, reduced heat production, and superior image quality that enables distortion-free visualization of examination areas.

Discover evolving trends in the dermatoscope treatment landscape @ Dermatoscope Recent Developments.

Looking ahead, the dermatoscope market is expected to witness continued innovation, with a focus on integrating artificial intelligence, enhancing digital imaging capabilities, and improving diagnostic accuracy. These advancements, coupled with increasing skin cancer awareness initiatives and growing demand for non-invasive diagnostic procedures, will likely sustain the market’s upward trajectory through 2030.

Table of Contents

1. Dermatoscopes Market Report Introduction

2. Dermatoscopes Market Executive Summary

3. Regulatory Analysis

4. Dermatoscopes Market Key Factors Analysis

5. Dermatoscopes Market Porter’s Five Forces Analysis

6. Dermatoscopes Market Layout

7. Dermatoscopes Market Company and Product Profiles

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dermatoscope Market Projected to Reach USD 2 Billion by 2030, Growing at a CAGR of 13.30% | DelveInsight

Chronic Kidney Disease Market Poised for Rapid Growth Amid FDA Drug Approvals | DelveInsight

The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others.

DelveInsight’s “Chronic Kidney Disease Market Insight, Epidemiology, and Market Forecast – 2034” report provides comprehensive insights into chronic kidney disease, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the 7MM (United States, EU4, United Kingdom, and Japan).

According to the report, the market size of chronic kidney disease across the 7MM was approximately USD 4.6 billion in 2023, and is projected to grow steadily through 2034. The United States emerged as the largest contributor, accounting for nearly USD 2.5 billion of the total market, significantly outpacing other key regions such as the EU4, the UK, and Japan. Within Europe, Germany held the leading position and is expected to maintain its dominance by 2034, followed closely by the UK. While Japan also captured a considerable share, the overall market landscape is being shaped by rising prevalence, better diagnostic rates, and the adoption of advanced treatment approaches across major geographies.

Download the chronic kidney disease market report to understand which factors are driving the CKD therapeutic market @ Chronic Kidney Disease Market Trends.

According to DelveInsight’s epidemiological analysis, the estimated total number of chronic kidney disease prevalent cases diagnosed in the 7MM was nearly 82 million in 2023, and this number is expected to increase significantly over the next decade. The US accounted for the highest total diagnosed prevalent cases of chronic kidney disease in 2023, with approximately 4 million cases. Further, stage 3 CKD represents the largest patient population segment in the 7MM.

Gender disparities in CKD prevalence and progression are becoming increasingly apparent, with women showing higher prevalence in early stages. Furthermore, age-specific data shows the highest prevalence among individuals aged 65 and older. These differential progression patterns highlight the need for gender- and age-specific approaches to CKD management and intervention.

Diabetes and hypertension remain the leading causes of CKD, while the prevalence increases substantially with age, with individuals over 65 years showing markedly higher rates compared to younger populations. Additionally, the increasing recognition of non-traditional risk factors, including obesity, environmental exposures, and certain medications, is reshaping our understanding of CKD epidemiology.

The chronic renal failure therapeutics landscape has evolved substantially in recent years, moving beyond traditional approaches focused solely on slowing disease progression to novel therapies targeting specific pathways. SGLT2 inhibitors, including FARXIGA (dapagliflozin) and INVOKANA (canagliflozin), have revolutionized renal disease management by demonstrating significant renoprotective benefits beyond glycemic control, substantially reducing the risk of kidney failure and cardiovascular events in CKD patients. The approval of KERENDIA (finerenone), a non-steroidal mineralocorticoid receptor antagonist, has further expanded treatment options by addressing inflammation and fibrosis pathways in diabetic kidney disease.

For renal anemia, the market has witnessed significant advancements with the approval of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, such as VAFSEO (Akebia Therapeutics) and EVRENZO (Astellas), which provide alternatives to traditional erythropoiesis-stimulating agents. These therapies offer improved convenience with oral administration and potentially reduced cardiovascular risks compared to injectable options. Additionally, KORSUVA (Cara Therapeutics) has addressed the significant burden of Uremic Pruritus (CKD-aP), substantially improving the quality of life for affected patients on hemodialysis.

According to DelveInsight’s analysis, the renal treatment pipeline is robust, with several therapies in various development stages targeting different aspects of renal disease progression and complications. Notable candidates include Ocedurenone (KBP Biosciences), a nonsteroidal mineralocorticoid receptor antagonist being investigated for the treatment of resistant hypertension in patients with chronic kidney disease; Sparsentan (Travere Therapeutics), a dual endothelin and angiotensin receptor antagonist showing promise in IgA nephropathy and focal segmental glomerulosclerosis; and atrasentan (Chinook Therapeutics), an endothelin A receptor antagonist demonstrating potential in proteinuric kidney diseases.

Cell and gene therapies are also emerging as potential transformative approaches, with candidates like FCR001 (Talaris Therapeutics) being investigated for inducing immune tolerance in kidney transplant recipients. Additionally, several bispecific antibodies targeting inflammatory pathways involved in CKD progression are advancing through early clinical trials, potentially offering new mechanisms to address kidney inflammation and fibrosis.

Unlock which chronic kidney disease emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Chronic Kidney Disease Market Insights.

The chronic renal disease treatment landscape has seen significant advancements in early 2025, marked by key regulatory milestones and expanded therapeutic options.

In March 2025, the FDA expanded the approval of Furoscix (furosemide injection, scPharmaceuticals, Inc.) to include the treatment of edema in adult CKD patients, including those with nephrotic syndrome, with availability expected by April 2025.

Additionally, in January 2025, Semaglutide (Novo Nordisk) received FDA approval for a new indication to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD, further enhancing patient care.

Unicycive Therapeutics announced in November 2024 that the FDA has accepted its New Drug Application for Oxylanthanum Carbonate (OLC), targeting hyperphosphatemia in CKD patients on dialysis, with a PDUFA action date set for June 28, 2025. These developments underscore a rapidly evolving CKD market, offering new hope and improved outcomes for patients.

Discover evolving trends in the chronic kidney disease treatment landscape @ Chronic Kidney Disease Recent Developments.

Despite these advancements, significant challenges persist in the CKD treatment landscape. Early diagnosis remains elusive, with many patients identified only after substantial kidney damage has occurred. Additionally, the complex, multifactorial nature of renal diseases often requires combination therapies, creating concerns about polypharmacy, drug interactions, and economic burden. DelveInsight’s analysis emphasizes the need for biomarker-driven, personalized treatment approaches and more effective strategies for early intervention to address these unmet needs.

Looking ahead, the chronic kidney disease market is poised for substantial transformation, with multiple late-stage therapies expected to gain approval in the coming years. Combination regimens leveraging complementary mechanisms of action are likely to become standard practice, offering more comprehensive kidney protection. Additionally, the integration of artificial intelligence in predictive modeling and treatment selection promises to enhance personalized care, potentially revolutionizing CKD management by enabling earlier intervention in high-risk populations and optimizing therapy selection based on individual patient characteristics and disease subtypes.

Table of Contents

1. Key Insights

2. Report Introduction

3. CKD Market Overview at a Glance

4. CKD Epidemiology and Market Forecast Methodology

5. Key Events

6. CKD Executive Summary

7. Disease Background and Overview of Chronic Kidney Disease (CKD)

8. CKDEpidemiology and Patient Population

9. CKD Patient Journey

10. CKD Marketed Drugs

11. CKD Emerging Drugs

12. CKD: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. CKD Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

Related Reports

Chronic Kidney Disease Pipeline Insight

Chronic Kidney Disease Pipeline Insight provides comprehensive insights about the CKD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the CKD companies, including AstraZeneca (LON: AZN), Eli Lilly and Company (NYSE: LLY), Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta (ASX: 1AD), Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics (NASDAQ: DMAC), Roche (SWX: ROG), MC2 Therapeutics, Allena Pharmaceuticals (NASDAQ: ALNA), Regulus Therapeutics (NASDAQ: RGLS), UnicoCell Biomed (TPE: 6794), and Regeneron Pharmaceuticals (NASDAQ: REGN), among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Market Poised for Rapid Growth Amid FDA Drug Approvals | DelveInsight

Bullous Keratopathy Market Poised for Robust Growth at an 11.5% CAGR Over the Coming Decade | DelveInsight

The bullous keratopathy treatment market is projected to experience substantial growth over the coming decade, driven by an aging population, increasing prevalence of cataract surgeries, glaucoma procedures, and novel pharmaceutical interventions by key bullous keratopathy players such as Aurion Biotechnologies, Emmecell, Trefoil Therapeutics, and Cellusion, among others.

DelveInsight’s “Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of bullous keratopathy, historical and forecasted epidemiology, as well as the bullous keratopathy market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report provides detailed insights into current treatment practices, bullous keratopathy emerging therapies, and market dynamics from 2020 to 2034, offering a comprehensive assessment of this evolving therapeutic landscape. This analysis serves as a crucial resource for stakeholders seeking to understand market potential and identify strategic opportunities in the bullous keratopathy treatment market.

According to DelveInsight’s market assessment, the bullous keratopathy market size in the 7MM was valued at approximately USD 14 million in 2023 and is projected to grow at a robust CAGR of 11.5% during the forecast period (2024-2034). The US currently dominates the market, followed by the EU4 and UK regions, with Japan representing a significant growth opportunity due to its aging population and high prevalence of cataract surgeries. This market expansion reflects increasing disease awareness, improved diagnostic capabilities, and the anticipated launch of novel therapeutic interventions addressing the substantial unmet needs in bullous keratopathy management.

Download the bullous keratopathy market report to understand which factors are driving the bullous keratopathy therapeutic market @ Bullous Keratopathy Market Trends.

The report provides comprehensive epidemiological insights, revealing that approximately 200K diagnosed prevalent cases of bullous keratopathy were recorded across the 7MM in 2023, with the US accounting for the largest share at 41% of total cases. According to DelveInsight’s analysis, the prevalence is expected to increase steadily through 2034, primarily due to demographic shifts toward an aging population and the rising volume of cataract surgeries, intraocular lens implantations, and other invasive ocular procedures that can damage corneal endothelial cells.

The current bullous keratopathy treatment landscape primarily relies on corneal transplantation techniques, particularly endothelial keratoplasty (EK) procedures, including Descemet’s stripping automated endothelial keratoplasty (DSAEK) and Descemet’s membrane endothelial keratoplasty (DMEK). While these surgical interventions can effectively restore vision, they face significant challenges, including limited donor cornea availability, risk of graft rejection, surgical complications, and substantial healthcare costs. Symptomatic management with hypertonic saline solutions, bandage contact lenses, and lubricating eye drops provides temporary relief but fails to address the underlying endothelial cell dysfunction, highlighting the critical need for innovative therapeutic approaches.

Discover emerging trends in the bullous keratopathy treatment landscape @ Bullous Keratopathy Therapies Market.

The bullous keratopathy pipeline has shown promising advancement in recent years, with several innovative therapies in clinical development. Aurion Biotechnologies (NYSE: AURN) has emerged as a pioneer with VYZNOVA, a cell therapy product launched in Japan in September 2024, which represents a significant step forward in treating bullous keratopathy. Emmecell is progressing with EO2002, completing the final dose administration for the last patient in its US Phase I trial in April 2024, with a Phase III pivotal study scheduled for the first quarter of 2025. Additional promising candidates include TTHX1114 (NM141) by Trefoil Therapeutics and CLS001 by Cellusion, which aim to either regenerate corneal endothelial cells or provide novel mechanisms to address corneal edema and bullae formation.

Unlock which bullous keratopathy emerging therapy is expected to capture the largest market share in 7MM by 2034. Visit the Bullous Keratopathy Market Insights.

Recent developments in the bullous keratopathy clinical trials landscape have generated significant optimism. In January 2025, preliminary results from a Phase II study of a novel Rho-kinase inhibitor demonstrated substantial improvement in corneal clarity and thickness in patients with moderate bullous keratopathy, suggesting potential as a non-surgical intervention. Additionally, early data from a corneal endothelial cell expansion technology being developed through a collaboration between academic research institutions and industry partners has shown promising results in ex vivo studies, potentially offering a solution to donor tissue shortages for transplantation procedures.

Despite these advancements, significant challenges remain in the bullous keratopathy treatment market. Limited disease awareness among primary care physicians and general ophthalmologists can lead to delayed diagnosis and intervention. The complex nature of corneal endothelial cell biology presents hurdles for developing targeted pharmacological approaches, while high treatment costs and limited reimbursement pathways create access barriers, particularly for innovative cell therapies. DelveInsight’s analysis emphasizes that addressing these challenges will require coordinated efforts among healthcare stakeholders, including enhanced physician education, streamlined regulatory pathways for cell-based therapies, and the adoption of value-based reimbursement models.

Looking ahead, the bullous keratopathy market is poised for transformation through the advancement of cellular therapies, targeted pharmacological agents, and tissue engineering approaches. The integration of artificial intelligence in diagnosing and monitoring disease progression is expected to enhance treatment planning and outcomes assessment. Additionally, combination therapies targeting multiple aspects of corneal endothelial dysfunction may provide more comprehensive and durable benefits than current single-modality approaches. With increasing investment in research and development, along with a greater focus on this previously underserved condition, patients with bullous keratopathy can expect expanded treatment options and an improved quality of life in the coming decade.

Table of Contents

1. Key Insights

2. Report Introduction

3. Bullous Keratopathy Market Overview at a Glance

4. Methodology of Bullous Keratopathy Epidemiology and Market

5. Executive Summary of Bullous Keratopathy

6. Key Events

7. Bullous Keratopathy Background and Overview

8. Bullous Keratopathy Patient Journey

9. Bullous Keratopathy Epidemiology and Patient Population

10. Bullous Keratopathy Marketed Drugs

11. Bullous Keratopathy Emerging Drugs

12. Bullous keratopathy: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT

15. Bullous Keratopathy Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bullous Keratopathy Market Poised for Robust Growth at an 11.5% CAGR Over the Coming Decade | DelveInsight

BOOX Unveils Go 7 Series: Portable eReaders for Immersive Reading and Instant Idea Capture

Onyx BOOX

BOOX is thrilled to unveil the Go 7 series, the latest addition to its esteemed Go Series. It features Go 7 and Go Color 7 (Gen II), Android-based eReaders with writing capabilities for immersive reading and instant idea capture. Retaining the 7-inch size of the Go Color 7, both models inherit the sleek and minimalist design philosophy of the Go Series, emphasizing simplicity and portability.

The Go Color 7 (Gen II) features an E Ink Kaleido 3 display, renowned for its true-to-life color display, rendering soft hues at 150 PPI and crisp black-and-white content at 300 PPI. This makes it ideal for comic enthusiasts and readers who enjoy visually rich content. Meanwhile, the Go 7 boasts a Carta 1300 monochrome display with a resolution of 300 PPI, offering sharp text clarity that mimics traditional paper. Both models are equipped with adjustable front lights, ensuring comfortable reading in any lighting condition.

For the first time in BOOX’s 7-inch eReader lineup, both models feature handwriting capabilities. With the BOOX InkSense stylus, users can effortlessly jot down thoughts, highlight text, and mark up books. This addition provides a dynamic and engaging experience beyond reading, whether managing a grocery list, outlining a travel itinerary, or capturing sudden inspirations in the Notes app. This functionality ensures that users stay organized while on the go.

Onyx BOOX

Running on Android 13, both, Go 7 and Go Color 7 (GenII) provide access to the Google Play Store, enabling users to install their favorite apps for reading, podcasts, or leisurely activities. With 4GB of RAM and 64GB of internal storage (expandable via microSD), these devices are built to handle a wide range of apps and documents seamlessly.

At just 195g, both models are compact and lightweight, designed for comfortable one-handed use with wide bezels and new ergonomic page-turn buttons. The paperlike textured back provides a secure grip while maintaining a sleek aesthetic. The Go 7 comes in 2 colors, sophisticated black and white, while the Go Color 7 (Gen II) is available in a sleek black (navy blue) finish. Both models feature a water-repellent design for protection against spills and light rain.

Onyx BOOX

The Go 7 and Go Color 7 (Gen II) run on Android 13 and feature handwriting capabilities along with an eye-friendly display. They embody the slogan “Grab Right, Go Light,” offering a lightweight build that eases the weight on both hands and mind. Whether commuting, relaxing at a café, or exploring the outdoors, both provide a delightful experience beyond reading.

The Go Color 7 (Gen II) is expected to be released soon. In the meantime, the Go 7 is available for purchase at the official BOOX Shop.

About Onyx BOOX

BOOX is a global leading E Ink electronic brand of Onyx that specializes in E Ink tablets and monitors. It offers 6inch to 13.3inch E Ink products to assist aspiring, persistent, and innovative users in becoming more productive in work and study without straining their eyes. With cutting-edge hardware and advanced software, BOOX is the world’s only E Ink electronic brand that combines E Ink with Android and provides maximum flexibility. More product information can be found at shop.boox.com.

Media Contact
Company Name: Senmer News Wire
Contact Person: Arthur
Email: Send Email
Country: United States
Website: https://www.senmer.com/news

Saela Pest Control Expands Services in Merriam with Industry-Leading Solutions

Saela Pest Control Expands Services in Merriam with Industry-Leading Solutions
Saela Pest Control, a trusted name in advanced pest management, announces expanded service coverage in Merriam, Kansas. With a strong reputation for delivering efficient and effective pest control solutions, the company continues to raise industry standards for residential and commercial properties alike.

MERRIAM, KS – April 26, 2025 – Residents and businesses in Merriam seeking reliable pest management can now access expert services through Pest Control Merriam. Saela’s approach is rooted in science-backed treatments and proactive strategies, ensuring long-term prevention of common and complex infestations.

Known for its professionalism and commitment to customer satisfaction, Saela Pest Control is also a top result for those searching Pest Control Near Me. The company’s technicians are highly trained and equipped with the latest tools to target pests at the source, offering protection from ants, rodents, cockroaches, spiders, and more.

For local residents needing fast response times and certified professionals, the company provides a convenient solution through its Exterminator Near Me services. Each treatment is customized based on property type, pest threat level, and environmental safety, making Saela a preferred choice in the Merriam area.

The expansion highlights Saela Pest Control’s dedication to innovation, safety, and community health. The company continues to grow its footprint by responding to increasing demand for effective pest control in suburban neighborhoods and urban environments.

Media Contact
Company Name: Saela Pest Control
Contact Person: John Frandsen
Email: Send Email
Phone: (913) 398-3182
Address:6230 Merriam Dr
City: Merriam
State: KS
Country: United States
Website: https://saelapest.com/merriam-pest-control/

Mike Walsh Painting and Decorating Delivers Premier Painting Services in Lake Geneva

Mike Walsh Painting and Decorating Delivers Premier Painting Services in Lake Geneva
Mike Walsh Painting and Decorating, a trusted name in the painting industry, continues to provide exceptional residential and commercial painting services in Lake Geneva and the surrounding areas. With a commitment to quality craftsmanship and customer satisfaction, the company remains a top choice for those seeking professional painting solutions.

Lake Geneva, WI – April 26, 2025 – As leading Painters Lake Geneva, the team at Mike Walsh Painting and Decorating specializes in both interior and exterior projects, utilizing high-quality materials and expert techniques to achieve stunning results. Each project is approached with precision and attention to detail, ensuring that every surface receives a flawless finish that enhances both aesthetics and durability.

Recognized as one of the most reliable Painting Contractors Lake Geneva, the company offers a range of services, including residential repaints, commercial painting, cabinet refinishing, and custom finishes. With years of experience in the industry, the professionals at Mike Walsh Painting and Decorating understand the importance of proper preparation, premium products, and meticulous application to deliver long-lasting and visually appealing results.

Homeowners searching for expert House Painters Lake Geneva can rely on Mike Walsh Painting and Decorating for top-tier services tailored to individual needs. Whether revitalizing an outdated home interior or refreshing an exterior façade, the team ensures seamless execution from start to finish. Attention to detail, efficient project management, and superior craftsmanship set the company apart in the competitive painting industry.

For more information about Mike Walsh Painting and Decorating’s services or to schedule a consultation, visit their website today. Experience the difference that professional painting services can make in transforming any space with precision and excellence.

Media Contact
Company Name: Mike Walsh Painting and Decorating
Contact Person: Mike Walsh
Email: Send Email
Phone: (262) 204-7622
City: Lake Geneva
State: WI 53147
Country: United States
Website: https://mikewalsh.pro/